Matthew Klein
Chief Executive Officer chez PTC THERAPEUTICS, INC.
Fortune : 7 M $ au 31/03/2024
Profil
Matthew B.
Klein is currently the President, Chief Executive Officer & Director at PTC Therapeutics, Inc. He is also an Independent Director at Clearpoint Neuro, Inc. and a Clinical Associate Professor at Stanford University.
Previously, he served as the Chairman-Restorative Burn Surgery at the University of Washington.
He was also a Director at BioElectron Technology Corp.
from 2019 to 2020 and the Chief Medical Officer & Senior Vice President at Edison Pharmaceuticals, Inc. Dr. Klein completed his undergraduate degree at the University of Pennsylvania, his doctorate at Yale University, and his graduate degree at UW School of Public Health.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PTC THERAPEUTICS, INC.
0,29% | 19/04/2024 | 225 807 ( 0,29% ) | 7 M $ | 31/03/2024 |
CLEARPOINT NEURO, INC.
0,05% | 18/03/2024 | 12 272 ( 0,05% ) | 83 450 $ | 31/03/2024 |
Postes actifs de Matthew Klein
| Sociétés | Poste | Début |
|---|---|---|
| CLEARPOINT NEURO, INC. | Director/Board Member | 16/04/2020 |
| PTC THERAPEUTICS, INC. | Chief Executive Officer | 22/03/2023 |
| Stanford University | Corporate Officer/Principal | - |
Anciens postes connus de Matthew Klein
| Sociétés | Poste | Fin |
|---|---|---|
BioElectron Technology Corp.
 BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services BioElectron Technology Corp. is a clinical-stage biotechnology company, which engages in the research and development of therapeutics for inherited mitochondrial disease. The company was founded in 2005 and is headquartered in Mountain View, CA. | Chief Executive Officer | 01/01/2019 |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Edison Pharmaceuticals, Inc.
 Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edison Pharmaceuticals, Inc. developed drugs to treat mitochondrial diseases. It offers EPI-743 and EPI-A0001, an orally absorbed small molecules. The company was founded by Guy Miller in 2005 and was headquartered in Mountain View, CA. | Chief Tech/Sci/R&D Officer | - |
Formation de Matthew Klein
| University of Pennsylvania | Undergraduate Degree |
| Yale University | Doctorate Degree |
| UW School of Public Health | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| CLEARPOINT NEURO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Edison Pharmaceuticals, Inc.
Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edison Pharmaceuticals, Inc. developed drugs to treat mitochondrial diseases. It offers EPI-743 and EPI-A0001, an orally absorbed small molecules. The company was founded by Guy Miller in 2005 and was headquartered in Mountain View, CA. | Health Technology |
BioElectron Technology Corp.
BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services BioElectron Technology Corp. is a clinical-stage biotechnology company, which engages in the research and development of therapeutics for inherited mitochondrial disease. The company was founded in 2005 and is headquartered in Mountain View, CA. | Commercial Services |
